ReviewEmerging infectious diseases2023
Clinical Manifestations and Genomic Evaluation of Melioidosis Outbreak among Children after Sporting Event, Australia.
Review in Emerging infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Travel-Associated Melioidosis in Non-Endemic Regions: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2025Pooled it
- Omitting the Eradication Phase of Treatment of Adults with Melioidosis: A Pilot, Single-Center Randomized Controlled Trial.Open forum infectious diseases · 2026Article
- Dry Season Melioidosis in the Tropical North of Australia.Pathogens (Basel, Switzerland) · 2026Article
- Global dispersal of Burkholderia pseudomallei and the evolving endemicity of melioidosis in the United States of America.PLoS neglected tropical diseases · 2026Review
- Rainfall-Driven Mobilisation of Clinically RelevantPathogens (Basel, Switzerland) · 2026Article
- Microbiological and Clinical Features of Patients with Cellulitis in Tropical Australia: Disease Severity Assessment and Implications for Clinical Management.The American journal of tropical medicine and hygiene · 2025Article
- The Association Between Statin Therapy and the Subsequent Clinical Course of Patients With Melioidosis.Journal of tropical medicine · 2025Article
- The Evolving Global Epidemiology of Human Melioidosis: A Narrative Review.Pathogens (Basel, Switzerland) · 2024Review
- The characteristics and clinical course of patients with melioidosis and cancer.PLoS neglected tropical diseases · 2024Article
- Bone and joint infections due to melioidosis; diagnostic and management strategies to optimise outcomes.PLoS neglected tropical diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melioidosis, caused by the environmental gram-negative bacterium Burkholderia pseudomallei, usually develops in adults with predisposing conditions and in Australia more commonly occurs during the monsoonal wet season. We report an outbreak of 7 cases of melioidosis in immunocompetent children in Australia. All the children had participated in a single-day sporting event during the dry season in a tropical region of Australia, and all had limited cutaneous disease. All case-patients had an adverse reaction to oral trimethoprim/sulfamethoxazole treatment, necessitating its discontinuation. We describe the clinical features, environmental sampling, genomic epidemiologic investigation, and public health response to the outbreak. Management of this outbreak shows the potential benefits of making melioidosis a notifiable disease. The approach used could also be used as a framework for similar outbreaks in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.